CBAC-01 is under clinical development by CHA Biotech and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect CBAC-01’s likelihood of approval (LoA) and phase transition for Stroke took place on 08 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CBAC-01 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

CBAC-01 overview

CBAC-01 is under development for the treatment of stroke, premature ovarian failure and low back pain caused due to lumbar intervertebral disc degeneration. Stem cells obtained from embryos and foetus are thought to be best because they are more likely to survive transplantation than those obtained from children or adults. It is administered intravenously. It acts by targeting interleukin 1 receptor (IL1R). It also comprises of enhanced umbilical cord adherent stem cells.  It was also under development for the treatment of foot ulcers.

CHA Biotech overview

CHA Biotech, formerly CHA Bio & DIOSTECH, is a biotechnology company that offers cell therapeutics development, bio insurance, cord blood, and stem cell banking solutions. Its R&D pipeline provides research in the therapeutic areas of age-related macular degeneration, intermittent claudication, stroke, Stargardt degeneration, Alzheimer’s disease, disk degeneration and others. CHA Biotech provides a bio-medical complex system that helps in managing cord blood collection, treatment, and transplantation; and also conducts ongoing research on cord blood-based therapeutics for treating incurable diseases using adult stem cells, embryonic stem cells and immune cells. The company also provides hospital IT management services across Japan. CHA Biotech is headquartered in Seongnam, Gyeonggido, South Korea.

Quick View CBAC-01 LOA Data

Report Segments
  • Innovator
Drug Name
  • CBAC-01
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Cardiovascular
  • Dermatology
  • Musculoskeletal Disorders
  • Women’s Health
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.